申请人:Merck & Co. Inc.
公开号:US05686478A1
公开(公告)日:1997-11-11
Novel derivatives of the general structural Formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, complications of diabetes, migraine, bone resorption, and inflammatory diseases, including Raynaud's disease and asthma.
通用结构式I的新型衍生物具有内皮素拮抗剂活性,因此可用于治疗心血管疾病,如高血压、肺动脉高压、缺血后肾衰竭、血管痉挛、脑和心脏缺血、心肌梗死、内毒素休克、良性前列腺增生、糖尿病并发症、偏头痛、骨吸收和炎症性疾病,包括雷诺氏病和哮喘。